



Thursday, 31 March 2022

Implementation of scheme of arrangement

Australian Pharmaceutical Industries (ASX:API) ("API") confirms that the scheme of arrangement, under which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, is to acquire 100% of the shares in API that it does not already own ("Scheme"), was implemented today.

WFM Investments Pty Ltd has now acquired all the issued shares in API.

The Special Dividend was paid on 29 March 2022 to API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Friday, 25 March 2022 and the balance of the Scheme consideration was paid today to all API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Tuesday, 29 March 2022.

With effect from the implementation of the Scheme, Kenneth Gunderson-Briggs, Lee Ausburn, Jennifer Macdonald, Janine Allis, Clive Stiff and George Tambassis have resigned as directors of API.

As previously announced, trading in API shares on the ASX was suspended from the close of trading on Tuesday, 22 March 2022. API has applied to the ASX to have quotation of its shares terminated and for API to be removed from the official list of the ASX, with effect from the close of trading on Friday, 1 April 2022.

This announcement is authorised for release by the Board of Directors of API.

For further information:

Investors

Carolyn Ireland
API
T: +61 403 045 905

Media

Gabriel McDowell
Res Publica
T: +61 417 260 918



Australian Pharmaceutical Industries Limited
250 Camberwell Road Camberwell VIC 3124 Australia
T: +61 3 8855 3000 www.api.net.au ACN 000 004 320